These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 12522440)
1. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Mastrangelo MJ; Lattime EC Cancer Gene Ther; 2002 Dec; 9(12):1013-21. PubMed ID: 12522440 [TBL] [Abstract][Full Text] [Related]
2. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
3. In situ cytokine gene transfection using vaccinia virus vectors. Lattime EC; Lee SS; Eisenlohr LC; Mastrangelo MJ Semin Oncol; 1996 Feb; 23(1):88-100. PubMed ID: 8607035 [TBL] [Abstract][Full Text] [Related]
4. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479 [TBL] [Abstract][Full Text] [Related]
6. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
10. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Zeh HJ; Bartlett DL Cancer Gene Ther; 2002 Dec; 9(12):1001-12. PubMed ID: 12522439 [TBL] [Abstract][Full Text] [Related]
12. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779 [TBL] [Abstract][Full Text] [Related]
13. Modulation of antitumor immune responses by hematopoietic cytokines. Waller EK; Ernstoff MS Cancer; 2003 Apr; 97(7):1797-809. PubMed ID: 12655538 [TBL] [Abstract][Full Text] [Related]
14. Local gene therapy of solid tumors with GM-CSF and B7-1 eradicates both treated and distal tumors. Collins CG; Tangney M; Larkin JO; Casey G; Whelan MC; Cashman J; Murphy J; Soden D; Vejda S; McKenna S; Kiely B; Collins JK; Barrett J; Aarons S; O'Sullivan GC Cancer Gene Ther; 2006 Dec; 13(12):1061-71. PubMed ID: 16874363 [TBL] [Abstract][Full Text] [Related]
15. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888 [TBL] [Abstract][Full Text] [Related]
16. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors. Tai KF; Chen PJ; Chen DS; Hwang LH J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087 [TBL] [Abstract][Full Text] [Related]
17. Nonviral cytokine gene therapy on an orthotopic bladder cancer model. Wu Q; Mahendran R; Esuvaranathan K Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526 [TBL] [Abstract][Full Text] [Related]
18. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Gordon EM; Chan MT; Geraldino N; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL Int J Oncol; 2007 Jun; 30(6):1297-307. PubMed ID: 17487349 [TBL] [Abstract][Full Text] [Related]
19. Systemic genetic transfer of p21WAF-1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex. Liu X; Tian PK; Ju DW; Zhang MH; Yao M; Cao XT; Gu JR Cancer Gene Ther; 2003 Jul; 10(7):529-39. PubMed ID: 12833133 [TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]